Reproductive Hormone Market 2019 Global Analysis, Growth, Trends, Size, Share, Opportunities, Regional Outlook With Industry Forecast To 2027
Artificially produced reproductive hormones are used for various medical reproductive conditions. There are few brands available in market which includes, Cenestin, Ogen, Femtrace, Menest (Pro), and Divigel. The reproductive hormones play major role in fertility and sexuality. In females, estrogen and progesterone are two important hormones that help them to manage their sex characteristics and play functional role in menstrual cycle, fertility, and pregnancy. Similarly, in males, testosterone is an important hormone that help men to develop sperm in the testes.
Get Sample PDF Brochure with Impact of COVID19: https://www.coherentmarketinsights.com/insight/request-sample/3185
The artificial production of such hormones is done by two methods, which include source analogue and recombinant hormones. In source analogue, the source of hormone is accessible easily, for example, the LH like analogue is urinary hCG. The LH preparation is extracted from the urine of pregnant women. The variation in such hormone may differ in batch-to-batch as per variation in bioactivity. Similarly, recombinant hormones are produced from transfected Chinese hamster ovary cells and purified by using immunoaffinity chromatography technique.
Reproductive Hormone Market – Drivers
The reproductive hormone market size is expected to increase over the forecast period, owing to rising drug approvals of reproductive hormones. For instance, in 2018, TherapeuticsMD Inc. received the U.S. FDA approval for its BIJUVA (Estradiol and Progesterone) Capsules for treatment of vasomotor symptoms associated with menopause.
Furthermore, increasing number of infertility in women is expected to drive growth of this market. For instance, in 2010, according to WHO, there were 48.5 million infertile couples, globally. Additionally, according to a survey conducted by Centers for Disease Control and Prevention, in between 2006-2010, 1 in 8 couples had faced problems of sustaining pregnancy in the U.S. Therefore, such increasing burden of infertility across the globe, is expected to drive growth of the reproductive hormone market.
Tailored Information as per niche requirement:
LIMITED TIME OFFER – Hurry Up!
Get Discount For Buyers UPTO 30% OFF On Any Research Report
Apply Promo Code “CMIFIRST1000” And Get Instant Discount Of USD 1000
Buy Now This Premium Report to Grow your Business @ https://www.coherentmarketinsights.com/insight/buy-now/3185
Reproductive Hormone Market – Restraints
Increasing drugs recalls is a major factor responsible for restraining growth of the reproductive hormone market. For instance, in 2017, Medisca Inc. voluntarily issued recalls for its range of hormone drugs including ESTRADIOL, USP Bulk (Hemihydrate), ESTRADIOL, ESTRONE, USP Bulk, and ESTRIOL, USP (Micronized) Bulk, due to lack of standard good manufacturing practices which was noted by U.S. FDA inspection.
Reproductive Hormone Market – Regional Analysis
On the basis of region, North America is expected to be dominant in the reproductive hormone market in forecasted periods, owing to increasing drug approval and launches of reproductive hormones in the U.S. For instance, AbbVie Inc. received U.S. FDA approval for ORILISSA (elagolix) drug for the treatment of moderate-to-severe pain associated with endometriosis. Similarly, in January 2019, Ferring Pharmaceuticals acquired the U.S. commercialization rights of Ganirelix Acetate Injection from Sun Pharmaceutical Industries Ltd. through addition of Ganirelix drug into its product portfolio. Through this strategy, Ferring Pharmaceuticals expanded its reproductive medicine portfolio offerings in the U.S. market.
Asia Pacific is expected to be the highest growing region in the reproductive hormone market over the forecast period. For instance, as per The Economist Intelligence Unit Limited 2019 report, the fertility rate of Southeast Asia fell from 5.5 to 2.4 in between 1970 to 2015. By 2030, it is projected to fall down to 2.1, which is attributed to decreasing fertility rate noted in few countries such as Malaysia, Vietnam, and Thailand, which were 1.90, 2.04, and 1.58, respectively in 2017.
Reproductive Hormone Market – Competitive landscape
Key players operating in the reproductive hormone market include, AbbVie Inc., Allergan plc, Pfizer Inc., Novo Nordisk A/S, Endo Pharmaceuticals Inc., and few others.
To understand Research Methodology, please click https://www.coherentmarketinsights.com/ongoing-insight/reproductive-hormone-market-3185
Reproductive Hormone Market – Taxonomy
The reproductive hormone market is segmented on the basis of hormone type, end-user, and region.
By Hormone Type
- Menopausal and Menstrual Disorders
- Premenstrual Syndrome (PMS)
- Specialty Clinics
- North America
- Latin America
- Asia Pacific
- Middle East
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
To know more about us, please visit our website – www.coherentmarketinsights.com
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
This content has been distributed via CDN Newswire press release distribution service. For press release enquires please mail us at email@example.com.
- CDN Newswire